

April 28 – 30, 2026 | Boston, MA

www.peptide-based-therapeutics-summit.com

SAVE UP TO \$1000
BY REGISTERING
BEFORE
JANUARY 9



3rd Annual

Peptide-Based Therapeutics Summit

Turbocharging Peptide Drug Discoveries into Life-Saving Treatments

Advancing the Discovery &
Development of Peptide Drugs
with Novel Screening, Chemistry,
Formulation & CMC to Improve
Permeability, Bioavailability &
Efficacy Across All Diseases

40+ Expert Speakers Include:



Tomi Sawyer
Chief Drug Hunter &
President
**Maestro
Therapeutics**



Ved Srivastava
Chief Technology
Officer
Perpetual Medicines



Cameron Pye
Chief Executive
Officer
Unnatural Products



Bradley Pentelute
Professor of
Chemistry
MIT



Annette Bak
Head of Advanced
Drug Delivery
AstraZeneca



Shelley Allen
Project Director
II, Immuno-
Pharmacology &
Peptide Discovery
Abbvie

Proud to Partner With:

Media Partner:



+1 617 455 4188 @ info@hansonwade.com

www.peptide-based-therapeutics-summit.com

[Peptide Therapeutics Group](#)



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Welcome to the Industry's Leading 3rd Peptide-Based Therapeutics Summit!

2nd Annual
**Peptide-Based
Therapeutics Summit**
April 28 – 30, 2026 | Boston, MA

The peptide therapy space is undergoing a surge in momentum with clinical progress of **Merck's** oral PCSK9 inhibitor and **Johnson & Johnson's** IL23R antagonist peptide, along with key investments including **Argenx** and **Unnatural Products** inking a £1.5Bn macrocyclic peptide deal. Peptide therapeutics are firmly back on the map as the next modality disrupting drug development.

As the peptide industry is beelining for success, the **Peptide Based Therapeutics Summit** returns to Boston for the **third year** as the most comprehensive, industry-dedicated peptide discovery and development conference, dedicated to showcasing the **hottest peptide subtypes from macrocycles to drug-conjugates and key advances in oral bioavailability**. With a brand new two-track agenda spotlighting **Drug Discovery** and **Formulation & CMC**, this is your ultimate one-stop-shop to advance your peptide design, chemistry, delivery and manufacturing strategies from concept to commercial success.

Stay ahead of the curve by joining **100+ stakeholders** from across all stages of peptide development including **Drug Discovery, Medicinal Chemistry, Computational Biology, Formulation, Drug Delivery, CMC** and more. It's time to pave the way to develop peptide drugs that are stable, permeable and bioavailable across all routes of administrations to supercharge your discovery efforts into efficacious peptide therapeutics across all diseases.

Key Benefits of Attending



Unearth the progress of artificial intelligence & computational methods to design & deliver peptides effectively, enhancing affinity & permeability, with insights from **Unnatural Products, Chugai Pharmaceuticals & Aizen Therapeutics**



Optimize screening & cell-based assays to identify high affinity hits & better understand compound permeability using mRNA, phage & yeast libraries, with insights from **Parabilis Medicines & A*STAR**



Improve macrocyclic & traditional peptide formulation strategies from oral to injectables & beyond with optimal bioavailability & half-life stability, with insights shared by **Vivtex, Cyprumed & Eli Lilly**



Revolutionize the design of peptide-based vectors for targeted, intracellular & safe delivery of different payloads including proteins, RNA & oligonucleotides, with insights from **Divincell & Feldan Therapeutics**



Unravel the immunogenicity & DMPK properties from peptide discovery stage to development across model systems towards clinical success with insights from **Merck & Co, Abbvie & US Pharmacopoeia**

Why Our Speakers Love This Summit

“This summit will provide a deep learning experience for all peptide drug hunters and an opportunity to meet accomplished R&D leaders as well as share their scientific work as speakers or via poster presentations”



Tomi Sawyer,
Maestro Therapeutics

“A great venue to connect with global experts, discuss peptide therapeutics, and inspire new ideas and collaborations”



Wen Jianzhong,
Merck & Co

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

What's New For 2026?



2nd Annual
Peptide-Based
Therapeutics Summit

April 28 – 30, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



Brand-New Two-Track Agenda

Drug Discovery



Overcome the challenges of crystal structure characterization, novel target identification and novel computational methods to unlock peptide design, structure and functionality with insights from:

**SAPIENCE
THERAPEUTICS**



PERPETUAL MEDICINES

Formulation & CMC



Tackle oral bioavailability and route of administration challenges from enhanced permeation, cellular targeting and clinical safety with insights from:



VIVTEX

CYPRUMED®
changing biodelivery



4 Deep-Dive Workshops

Hear the latest advancements in peptide innovation across in-depth workshops solving emerging peptide challenges, from leveraging AI for peptide design, harnessing new tools from mRNA and phage display for peptide screening, leveraging peptides for drug conjugation and optimizing the peptide analytical toolbox for effective translatability.



**Artificial Intelligence
for Peptide Design**



**Peptide-Drug
Conjugates**



**Novel Screening
Methods**



**Analytical
Development for
Peptide Translation**



Key Pharma Leaders Attending in 2026

Hear firsthand from pharma giants as they deep dive into their perspectives on the peptide industry and case studies from macrocyclic discoveries, peptide-drug conjugate developments and oral peptide delivery to unlock the next wave of peptide drugs.



novo nordisk®

AstraZeneca



Lilly



CHUGAI



ucb



MERCK

Johnson & Johnson

abbvie



Business Development & Investment Panel

With the industry capitalizing from GLP-1 progress, to the potential of peptides across new disease indications, hear from leading biotech and investors as they empower you on forging alliances and seeking funding towards advancing peptide innovation and speed to clinic.

UNP

VIDA
ventures

Curie.Bio

Your Expert Speakers



2nd Annual
**Peptide-Based
Therapeutics Summit**

April 28 – 30, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Large Pharma Leaders



Pete Gough
Head of Research
Nimble Therapeutics
Head of Immuno-
Pharmacology & Peptide
Discovery
Abbvie



Shelley Allen
Project Director II,
Immuno-Pharmacology &
Peptide Discovery
Abbvie



Annette Bak
Head of Advanced Drug
Delivery
AstraZeneca



Atsushi Matsuo
Research Scientist
Chugai Pharmaceuticals



Byungkook Qook Lee
Research & Development
Scientist (Research
Advisor)
Eli Lilly



Sumit Arora
Senior Principal Scientist,
Oral Peptides
Johnson & Johnson



Maria Fawaz
Associate Principal
Scientist, DMPK
Merck & Co



Kaustav Biswas
Senior Principal Scientist,
Boston Discovery
Chemistry
Merck & Co



Wen Jianzhong
Senior Principal Scientist
& Group Lead
Merck & Co



Chen Liang
Senior Scientist II
Novo Nordisk



Philip Jonas Sassene
Scientific Director
Novo Nordisk



Olivera Grubisha
Senior Group Leader,
In Vitro Pharmacology
UCB

Peptide Drug Hunters & Developers



Phil Brandish
Chief Scientific Officer
AI Proteins



Christopher Brown
Principal Investigator
**Agency for Science,
Technology and
Research (A*STAR)**



Ajay Kshatriya
Chief Executive Officer
Aizen Therapeutics



Breena Fraga-Walton
Senior Scientist
Circle Pharma



Florian Föger
Chief Executive Officer
Cyprumed



David Earp
President & Chief
Executive Officer
Circle Pharma



Gilles Divita
Chief Executive Officer
Divinell



Michael Lipp
Chief Technology Officer
Decoy Therapeutics



Barbara Hibner
Chief Scientific Officer
Decoy Therapeutics

Your Expert Speakers



2nd Annual
**Peptide-Based
Therapeutics Summit**

April 28 – 30, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



Charles Johannes
Founder, President & Chief
Scientist
EPOC Scientific



Soultan Al-Halifa
Director R&D,
Biopharmaceutical
Chemistry
Feldan Therapeutics



Hideki Tomioka
Chief Scientific Officer,
Member of the Board,
Director of Research &
Development
FunPep



Vincent Jannin
R&D Director & Head of
Innovaform® Accelerator
Lonza Capsugel



Bradley Pentelute
Professor of Chemistry
MIT



Tomi Sawyer
Chief Drug Hunter &
President
Maestro Therapeutics



Kevin McDonnell
Senior Vice President,
Chemistry & Discovery
Newco



Justin Lawrie
Senior Scientist
Parabilis Medicines



Immanuel Lerner
Founder & Chief Executive
Officer
Pepticom



Ved Srivastava
Chief Technology Officer
Perpetual Medicines



David White
Senior Vice President,
Head of Drug Discovery
ProteinQure



Sam Hong
Senior Director, Head of
Platform
**Rapafusyn
Pharmaceuticals**



Barry Kappel
Founder, President & Chief
Executive Officer
Sapience Therapeutics



David Brayden
Professor of Advanced
Drug Delivery
**University College
Dublin**



Cameron Pye
Chief Executive Officer
Unnatural Products



Joshua Schwochert
Chief Scientific Officer
Unnatural Products



Thomas von Erlach
Co-Founder & Chief
Scientific Officer
Vivtex



Peter Knauer
Distinguished Fellow, CMC
Xeris Biopharma

Investors & Industry Advisors



Antoine Henninot
Senior Director, Drug
Maker & Peptide
Chemistry
Curie.Bio



Mi Cai
Patent Attorney
Foley Hoag



Kevin Carrick
Senior Director Global
Biologics
US Pharmacopoeia



Julie Zhang
Team Lead, Principal
Scientist, Global Biologics
US Pharmacopoeia



Alex Loftis
Principal
Vida Ventures

Pre-Conference Workshop Day

Tuesday, April 28, 2026

9.00 Check In & Morning Coffee

Workshop A – Artificial Intelligence for Peptide Design

Converging AI/ML & Medicinal Chemistry to Effectively Predict & Advance Peptide Designs to Hit Functional Targets

10.00

Traditional peptide drug discovery has been hindered by limited native peptide ligands and time-consuming optimization processes. Artificial intelligence (AI) and machine learning (ML) are reshaping peptide-based drug discovery by enabling rapid design, activity prediction, and optimization of novel therapeutics.

This workshop will deep diving into the current AI/ML tools to design peptides, enabling optimization of their properties and high accuracy for downstream development.

Spotlight Case Study 1: How Can AI Compelment Empirical Methods in Peptide Drug Discovery?



Joshua Schwochert, Chief Scientific Officer, **Unnatural Products**

Spotlight Case Study 2: AI Design of Peptide Therapeutics: From Binders to Drugs



Ajay Kshatriya, Chief Executive Officer, **Aizen Therapeutics**

Spotlight Case Study 3: Opportunities & Challenges in Oral Peptide Design & Formulation Development



Immanuel Lerner, Founder & Chief Executive Officer, **Pepticom**

Workshop C – Peptide Drug Conjugates

Leveraging Peptide Drug Conjugates to Unlock New Targets & Expand Therapeutic Options in Oncology & Beyond

10.00

Peptide-Drug Conjugates (PDCs) are rising as a key next-generation therapeutic avenue, combining the precise targeting of peptides with the potency of cytotoxic drugs to treat cancers and other diseases. Several challenges to this technology however include their clinical potential due to stability, ligand binding specificity and target affinity which remains a significant challenge.

This workshop will provide insights into the future direction of PDCs as a promising application to unlock new targets and expand therapeutic applications.

Workshop Leader:



Chen Liang, Senior Scientist II, **Novo Nordisk**

Spotlight Case Study 1: Development of Peptide-Drug Conjugates for Targeted Tissue & Cell Type Delivery



David White, Senior Vice President, Head of Drug Discovery, **ProteinQure**

Spotlight Case Study 2: Design & Development of Peptide Conjugate Antiviral Therapeutics



Barbara Hibner, Chief Scientific Officer, **Decoy Therapeutics**



Michael Lipp, Chief Technology Officer, **Decoy Therapeutics**



12.30 Lunch Break & Networking

■ A great opportunity for peptide discovery and formulation scientists to understand how these aspects are co-dependent for translation ■

David Brayden, Professor of Advanced Drug Delivery,
University College Dublin



Pre-Conference Workshop Day

Tuesday, April 28, 2026

Workshop B – Screening Methods

Building mRNA, Phase Display & DNA-Encoded Chemical Libraries to Optimize Peptide Drug Discovery with Enhanced Therapeutic Functionality

1.30

Peptide-based therapeutics offer high specificity, potent activity, and relatively low toxicity making them attractive for targeting complex diseases. As the demand for innovative peptide drugs continues to grow, the need for advanced technologies and integrated approaches in early discovery becomes paramount.

This workshop will explore recent methodologies in peptide discovery screening including DNA-encoded library (DEL) technology, phage display, and mRNA display, to identify suitable targets and utilise the best strategy for accelerating therapeutic peptide research and development.

Spotlight Case Study 1: Linking Novel Site & Target Identification with Hit Discovery Using Genetically Encoded Libraries



Christopher Brown, Principal Investigator, **Agency for Science, Technology and Research (A*STAR)**

Spotlight Case Study 2: Integrating mRNA Display with Phage Display to Discover Helically Constrained (Helicon) Peptides



Justin Lawrie, Senior Scientist, **Parabilis Medicines**

Workshop D – Analytical Development

Refining Analytical Development Methods & Tools to Optimize DMPK Properties for Successful Translatability

1.30

In the dynamic landscape of peptide therapeutics, the development of robust analytical strategies is crucial for ensuring the efficacy when translating from discovery to clinic.

This workshop delves into the intricacies of analytical methodologies to provide a comprehensive overview of cutting-edge techniques and best practices essential for understanding metabolic properties and translatability across model systems.

Key topics include:

- Developing a robust analytical toolbox to optimise complex peptide therapeutics to enhance resolution and efficiency
- Examining the integration of purification tools and artificial intelligence-driven process optimization, facilitating rapid identification and removal of impurities while maximizing yield and purity of peptides
- Leveraging these tools to effectively assess DMPK properties to translate across model systems

Workshop Leaders:



Kevin Carrick, Senior Director Global Biologics, **US Pharmacopoeia**



Julie Zhang, Team Lead, Principal Scientist, Global Biologics, **US Pharmacopoeia**

3.30 End of Pre-Conference Workshop Day

“I am deeply interested in the emergence of the latest computational and machine learning approaches and how they complement more conventional library led approaches in peptide design. I believe the Peptide-Based Therapeutics Summit represents an ideal event where these different themes are brought together”

Christopher Brown, Principal Investigator, **A*STAR**

Conference Day One

Wednesday, April 29, 2026

2nd Annual
**Peptide-Based
Therapeutics Summit**
April 28 – 30, 2026 | Boston, MA

WELCOME

EXPERT
SPEAKERS

AGENDA

PARTNER
WITH US

REGISTER
YOUR PLACE



7.30 Check In & Morning Coffee



Charles Johannes
Founder, President &
Chief Scientist
EPOC Scientific

8.30 Chair's Opening Remarks

Unlocking the Discovery, Development & Outlook of The Peptide Therapeutics Industry Through Leadership Perspectives



David Earp
President & Chief
Executive Officer
Circle Pharma

8.35 An Outlook on Peptides: 2026 & Beyond



Bradley Pentelute
Professor of Chemistry
MIT

8.45 **The Infinite Loop: Machine Learning for Discovery, Delivery & Rapid Manufacturing of Potential Medicines**

- We're facing a challenge in the world of chemistry: Our lack of data is slowing down how we can use clever computer programs, known as machine learning, to create powerful new medicines
- Creating data highways from millions of small molecules, peptides and small proteins
- Using machine learning to discover and create new functional molecules quickly. Sometimes, these computer-designed molecules are even better than what we can make ourselves
- Developing an infinite loop where we automatically design, build, and test potential new medicines

9.15 Peptide Industry Leaders' Discussion – Unlocking Next Frontiers of Bioavailable Peptide-Based Therapeutics to Patients Faster

This your chance to hear from pioneering executive leaders the peptide space who will discuss their ambitions, strategies and challenges for peptide discovery, targets, indications and development of next generation of peptide drugs.

Key questions to be addressed include:

- What are the future opportunities, promising targets and applications on the horizon for peptide-drugs to achieve the next best in-market approval?
- Where is the next big wave heading after GLP-1 peptides?
- How will peptide-drugs compete against the biologics, antibody and small molecule markets as standards of care?

Moderated by:



Tomi Sawyer
Chief Drug Hunter &
President
Maestro Therapeutics

Panelists include:



David Earp
President & Chief
Executive Officer
Circle Pharma



Charles Johannes
Founder, President &
Chief Scientist
EPOC Scientific



Ved Srivastava
Chief Technology
Officer
Perpetual Medicines



Kaustav Biswas
Senior Principal Scientist,
Boston Discovery Chemistry
Merck Research Laboratories



Pete Gough
Head of Research
Nimble Therapeutics
Head of Immuno-Pharmacology &
Peptide Discovery
Abbvie



10.00 **Morning Break & Speed Networking**

This informal session provides the perfect opportunity to connect with industry frontrunners and key opinion leaders in the peptide-based therapeutics field. Get ready to engage with 100+ key stakeholders, swap your business cards and establish meaningful connections to build upon at the rest of the conference.

8



+1 617 455 4188



info@hansonwade.com



www.peptide-based-therapeutics-summit.com



Peptide Therapeutics Group



Conference Day One

Wednesday, April 29, 2026

Track A: Drug Discovery

Chair: **Olivera Grubisha**, Senior Group Leader, *In Vitro* Pharmacology, **UCB**

Pioneering the Potential of Cutting-Edge Computational Chemistry Approaches & Discovery Platforms to Enable Superior Peptide Breakthroughs

11.00 Computational Detail of Drug Discovery & Platform Technology Development for Cyclic Peptides

- Advancing hit-to-lead methods specialized for peptides
- Showcasing the formalization of drug-likeness criteria for orally available peptides
- Demonstrating the role of computer chemistry for platform technology development

Atsushi Matsuo, Research Scientist, **Chugai Pharmaceuticals**

New Data

11.30 Roundtable Discussion – Unearthing Peptide Structures with Improved Biological Mechanisms & Function Relationships to Expand Peptide Applications for Antibodies, Oligos & Beyond

- Delineating the possibilities and challenges of peptide drug prediction and design from a computational, medicinal chemistry and experimental perspective
- Discussing how to leverage current tools to examine structure-function relationships of novel peptides for antibody or oligo delivery
- Utilising sequence/structure-activity relationships (SAR) studies for lead selection and optimisation into the preclinical setting



12.00 Peptide Drug Hunting: Innovative Science & Technology Empowering Breakthrough Medicines

- Unveiling recent milestones in peptide drug discovery
- Boosting innovative R&D platforms from design to delivery
- Looking into the future challenges and opportunities

Tomi Sawyer, Chief Drug Hunter & President, **Maestro Therapeutics**

Track B: Formulation & CMC

Chair: **Philip Jonas Sassene**, Scientific Director, **Novo Nordisk**

Delivering Orally Bioavailable Peptides with Increased Stability & Half-Life Through Formulation Innovation

11.00 Advancements & Challenges in Oral Peptide Delivery

- Highlighting the challenges in oral delivery
- Presenting solutions on how to overcome these challenges with focus on using high throughput screening approaches
- Demonstrating case studies examples of increasing oral exposure in dogs using next generation formulations

Thomas von Erlach, Co-Founder & Chief Scientific Officer, **Vivtex**

11.30 Session Reserved For:

Capsugel®

Lonza

12.00 Translating the Oral Formulation of Peptides with Permeation Enhancers

- Reviewing the mechanisms of action of key intestinal permeation enhancers
- Spotlighting clinical development of oral peptide formulations with enhancers
- Re-purposing known excipients as permeation enhancers for oral peptide administration

David Brayden, Professor of Advanced Drug Delivery, **University College Dublin**

New Company

Conference Day One

Wednesday, April 29, 2026

2nd Annual **Peptide-Based Therapeutics Summit**
April 28 – 30, 2026 | Boston, MA



12.30 Lunch Break & Networking

Showcasing the Advances & Clinical Progress of Peptide-Based Therapeutics to Combat Cancer Indications

1.30 A Clinical Update on ST316 & Lucicebtide, First-In-Class Peptide Antagonists of β -catenin/BCL9 and C/EBP β , in Colorectal Cancer & Glioblastoma

- Presenting a clinical update on ST316, including the latest data from ongoing Phase 2 clinical program in colorectal cancer
- Spotlighting a clinical update on lucicebtide, including latest data update from Phase 2 clinical program in glioblastoma

Barry Kappel, Founder, President & Chief Executive Officer, **Sapience Therapeutics**

New Data

Unravelling Strategies to Maximise Peptide Bioavailability Across Cell Types & With Extended-Release Mechanisms

1.30 Oral Formulations for Macrocyclic Peptides & Linear GLP-1 Peptides

- Highlighting the impact of gastrointestinal targeting
- Improving oral bioavailability across the gut
- Strategies to reduce negative food impact

Florian Föger, Chief Executive Officer, **Cyprumed**

New Company

2.30 Opportunity For Sponsorship

Enquire with us:
sponsor@hansonwade.com

2.30 Session Reserved For:



2.40 Afternoon Networking Break & Scientific Poster Session

The scientific poster session is your prime time to share your work with peers from across peptide-specific disciplines to advance therapeutic progress using a diversity of approaches across discovery and development whilst forging potential collaborations. Submit your abstract [here](#). Submission deadline is April 10.

“ This summit is a modestly sized event with a high concentration of top tier peptide therapeutic scientists. It is very effective way to get updated on some of the latest advancements in our field and to be engaged in stimulating discussions ”

Kevin McDonell, Newco

Conference Day One

Wednesday, April 29, 2026

Harnessing the Best & Most Advanced Drug Delivery Systems & Routes of Administration for Successful Peptide Targeting Across Diseases

3.30 Fireside Peptide Delivery Discussion - Pushing the Limits of Peptide Formulation & Delivery from Novel Design to Effective Targeting Strategies for Better Patient Outcomes

- How to effectively design patient-centric peptide delivery formulations (oral vs injectable)?
- How to ensure novel peptide formulations can be scalable and cost efficient during the manufacturing process?
- Where will delivery innovations take the peptide field in the next 5 years?

Moderated by:



Maria Fawaz
Associate Principal
Scientist, DMPK
Merck & Co

Panelists include:



Thomas von Erlach
Co-Founder & Chief
Scientific Officer
Vivtex



David Brayden
Professor of Advanced
Drug Delivery
University College Dublin



Annette Bak
Head of Advanced
Drug Delivery
AstraZeneca



**Philip Jonas
Sassene**
Scientific Director
Novo Nordisk



Florian Föger
Chief Executive
Officer
Cyprumed



Sumit Arora
Senior Principal Scientist,
Oral Peptides
Johnson & Johnson



Vincent Jannin
R&D Director
& Head of
Innovaform®
Accelerator
Lonza Capsugel



Sumit Arora
Senior Principal
Scientist, Oral Peptides
Johnson & Johnson

4.15 Breaking Barriers - Redefining Oral Peptide Drug Delivery

More information coming soon



Charles Johannes
Founder, President &
Chief Scientist
EPOC Scientific

4.45 Chair's Closing Remarks

5.00 End of Conference Day One

Conference Day Two

Thursday, April 30, 2026



8.20 Check In & Morning Coffee



Cameron Pye
Chief Executive Officer
Unnatural Products

9.20 Chair's Opening Remarks

Envisioning the Success of Peptide-Based Therapeutics Enabled by Robust Biopharma Partnerships, Investments & Innovation Strategies

9.30 Business Development & Investment Panel Discussion — Exploring the Future of Peptide-Therapeutics Through Successful Funding Rounds, Biopharmaceutical Partnerships & Collaborations

The biopharmaceutical sector continues to innovate peptide discovery innovations, from new macrocycles to new delivery methods and are thriving on strategic alliances, which allow for cross-functional sharing of knowledge, and experience to advance peptide drugs to patients faster. Hear first-hand how investors and key biotechs are keeping up with the peptide momentum through investments, alliances and collaborations.

Key questions to be addressed include:

- How to strategize the complexities, risks and decision-making strategies for choosing the right platform to invest and advance innovative approaches in the peptide industry?
- What are the key areas and spaces that peptides can fill in the biotechnology sector?
- What does it take for a small biotech to survive and get noticed from an investor or big pharma?



Cameron Pye
Chief Executive Officer
Unnatural Products



Antoine Henninot
Senior Director, Drug Maker &
Peptide Chemistry
Curie.Bio



Alex Loftis
Principal
Vida Ventures



Mi Cai
Patent Attorney
Foley Hoag

10.00 The Peptide IP Landscape: Winning with Knowledge, Strategy & Innovation from Peptide Discovery to Development

- Harnessing critical understanding of regulatory and IP implications from drug discovery to formulation to ensure smooth market access for your peptide therapeutic
- Outlining the key IP bottlenecks for making changes to peptide drugs
- Defining the data packages required to be sufficient for IP submissions



10.30 Morning Break & Networking

Track A: Drug Discovery

Chair: **Kevin McDonnell**, Senior Vice President,
Chemistry & Discovery, **Newco**

Trailblazing the Next Wave of Peptide Design Through Physics & *De Novo* Approaches Towards Next Generation Peptide Therapeutic Modalities

11.00 From Traditional Peptide Discovery to Physics-Based AI Design - A Case Study of GLP-1 & β -Catenin Programs

- Showcasing a traditional drug discovery case study with example of GLP-1 class drugs highlighting the challenges with these approaches
- Demonstrating the application of AI/ML and physics-based tools to design novel peptide binders with drug-like properties, enabling multi-objective optimization toward a potential clinical candidate
- Presenting a case of current β -catenin project using physics-based AI approaches

Ved Srivastava, Chief Technology Officer, **Perpetual Medicines**

Track B: Formulation & CMC

Chair: **Annette Bak**, Head of Advanced Drug Delivery,
AstraZeneca

Harnessing Carrier Systems & Peptides as Drug Delivery Vehicles to Enable Laser-Focused Targeting of Peptide Drug Delivery

11.00 Unlocking a Peptide-Based Platform for Targeted Delivery of Therapeutic Agents

- Rationally designing and optimizing AI-driven peptide-vectors for targeted delivery of different payloads including peptide, protein and RNA
- Demonstrating safety and characterization of peptide-based nanoparticles for extrahepatic delivery of RNA
- Leveraging a peptide-based nanoparticle platform for systemic targeted delivery of therapeutic mRNA: T cell engineering and tumor selectivity

Gilles Divita, Chief Executive Officer, **Divincell**

New Company

Conference Day Two

Thursday, April 30, 2026

11.30 Discovery & Characterization of a Selective, Pure Antagonist of TNFR1

- Introducing *de novo* designed miniproteins as a next generation therapeutic modality
- Highlighting the application to antagonism of TNFR1
- Showcasing differentiation against existing therapies

Phil Brandish, Chief Scientific Officer, **AI Proteins**

11.30 Revolutionizing Intracellular Delivery with an Advanced Peptide-Based Platform for Clinical Success

- Pioneering endosomal escape through rationally designed peptide shuttles, enabling efficient delivery of small molecules, proteins, enzymes and oligonucleotides across diverse cell types
- Delivering functional biomolecules in different animal models
- Demonstrating clinical potential of the Feldan technology through *in vivo* data and progression to first-in-human trial for basal cell carcinoma

Soultan Al-Halifa, Director R&D, Biopharmaceutical Chemistry, **Feldan Therapeutics**

New Company



12.00 Lunch Break & Networking

Leveraging Case Study Examples of Peptide Discoveries to Achieving High Potency & Selectivity of Peptide-Based Therapeutics & Vaccines

1.00 Non-Degradative Macrocyclic Molecular Glue DELs

- RapaGlues are non-degrading molecular glues that recruit FKBP12 to form a new PPI ternary complex, successfully addressing the large portion of the undrugged cytosolic and transmembrane proteome
- Leveraging the RapaGlue Platform's proprietary DELs (over 8 billion compounds) and AI/ML-powered predictions for modeling-guided design to explore the topological diversity required to expand the range of targets
- RapaGlues promote the intracellular assembly of a protein-sized (+12kD) inhibitor, achieving a high success rate against multiple hard-to-drug targets with high potency, selectivity, and cell permeability

Sam Hong, Senior Director, Head of Platform, **Rapafusyn Pharmaceuticals**

New Data

Overcoming Bioanalytical & CMC Challenges in Analyzing & Effectively Scaling Peptides to Meet Clinical & Regulatory Expectations

1.00 Developing a Fit for Purpose Bioanalytical Strategy to Analyze a Cell-Penetrating Peptide: From Protein Precipitation to Solid Phase Extraction to Affinity Capture

- Introducing the properties of cell penetrating peptides
- Discussing the challenges of bioanalysis
- Utilizing a fit for purpose bioanalytical strategy: from protein precipitation to solid phase extraction to affinity capture

Wen Jianzhong, Senior Principal Scientist & Group Lead, **Merck & Co**

1.30 Active Immunotherapy Using Universal Epitopes

- Peptide vaccine technology involves prolonged suppression due to the production of anti-endogenous target protein antibody
- Peptide vaccines consist of highly immunogenic helper T cell epitope (AJP001) and B cell epitope originated from target protein
- Sharing the usefulness of antibody-inducing peptides based on non-clinical and clinical trial data of developed compounds

Hideki Tomioka, Chief Scientific Officer, Member of the Board, Director of Research & Development, **FunPep**

New Company

1.30 Using the XeriSol Formulation Platform for Peptide Parenteral Drug Delivery

- Presenting a non-aqueous, high concentration subcutaneous solution
- Enabling room temperature stability
- Showcasing excellent safety and toxicity profiles

Peter Knauer, Distinguished Fellow, CMC, **Xeris Biopharma**

New Company

Conference Day Two

Thursday, April 30, 2026



2.00 Afternoon Break & Networking

Unravelling the Challenges to Effectively Design & Formulate Cell Penetrable Peptide Therapies with Effective Pharmacology, Kinetics & Dynamics to Improve Patient Outcomes

2.30 Roundtable Discussion: From Discovery to Translation; Developing Cell Permeable & Orally Bioavailable Peptides with Optimal Pharmacology & DMPK

- Modifying amino acids to optimise target selectivity and cell membrane permeability to achieve the right pharmacology
- Modelling protein-protein interactions in the discovery to translate into the preclinical setting
- Analysing the pharmacokinetic and biodistribution properties of highly soluble orally bioavailable peptides to ensure efficacy when entering the clinic



Wen Jianzhong
Senior Principal Scientist & Group Lead
Merck & Co



Shelley Allen
Project Director II, Immuno-Pharmacology
& Peptide Discovery
Abbvie



Maria Fawaz
Associate Principal
Scientist, DMPK
Merck & Co

New Data

3.15 Peptide Inhibitor of Pan Corona Virus Fusion Protein

- Introducing of the Pan-Cov peptide inhibitor program and showcasing the peptide modality strategy
- Establishing *in vitro* and *ex vivo* efficacy assays for peptide optimization
- Discussing the challenges associated with peptide PK and biodistribution



Cameron Pye
Chief Executive Officer
Unnatural Products

3.45 Chair's Closing Remarks

4.00 End of 3rd Peptide-Based Therapeutics Summit 2026

“The summit will be an excellent opportunity to hear from thought leaders about advances in peptide-based therapeutics, the increasing importance of this modality, and where the field is heading in the next few years”

David Earp, President & Chief Executive Officer, Circle Pharma



Take the Spotlight & Partner with Us



2nd Annual
Peptide-Based
Therapeutics Summit

April 28 – 30, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

The Industry's Leading Peptide Drug Discovery & Development Platform to Help You Foster New & Nurture Existing Relationships

The peptide therapies space is experiencing a surge in momentum, with billion-dollar investments from pharma giants and Newcos establishing to build their own peptide platform and pipelines.

There has never been a more crucial time to claim your stake in this rapidly advancing market. The **3rd Peptide-Based Therapeutics Summit** is uniting **100+ leaders in discovering and developing a new generation of peptide drugs**, who are looking to partner with the top solution experts to ensure they keep ahead of the curve in areas including but not limited to:

Artificial
Intelligence

Peptide
Synthesis

Peptide
Formulation

Peptide
CDMO

Screening
Technology

How can this forum set your 2026 up for revenue-generating & partnership-forging success?



Uncover Peptide Market Trends

Learn from peptide industry pioneers about upcoming trends to remain best placed to forecast the future landscape and meet the needs of your target biopharma audience.



Showcase Your Technology Solutions

From peptide design optimization, ease of manufacture and increasing bioavailability, this is your unique opportunity to show the most influential minds in the peptide field how your platform accelerate towards commercial success.



Raise Your Brand Awareness

The opportunity to network with a niche audience of peptide industry decisionmakers and KOLs means you can secure invaluable face time and showcase your solutions to thought leaders in discovery chemistry.

Seniority of Attendees*



Chief/CXO/Founder – 17%

President/VP – 9%


Director/Head/Manager – 37%

Scientist – 30%

Professor – 4%

Other – 3%

Type of Companies Attendees*



Drug
Developers
Academia
& Research
Institutes
Service &
Solution
Providers
Consultants

*Statistics taken from the 2nd Peptide-Based Therapeutics Summit

Get Involved



Molly Biggin
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com



Peptide Partners.
Concept to Commercial.

Innovation Partner

With over 20 years of experience, **CPC Scientific** is a trusted partner to leading pharmaceutical, biotechnology companies, and esteemed universities. We specialize in synthetic GMP peptides, peptide-oligonucleotide conjugates, and offer a comprehensive range of custom and catalog products. Supporting clients from early drug discovery through clinical trials to commercialization, we adhere strictly to FDA and ICH CGMP guidelines. Our manufacturing capacity ranges from mg quantities to 100 kgs, ensuring seamless project integration and flexible, timely delivery.

www.cpcscientific.com



ARALEZ BIO

Exhibition Partner

Aralez Bio is a platform technology company harnessing the power of biocatalysis to sustainably generate exceptionally diverse noncanonical amino acids (ncAAs) from milligram to multi-kilogram scales. With the world's largest collection of novel ncAAs, Aralez Bio provides ultimate atomic-level control of peptide medicinal chemistry.

www.aralezbio.com



PeptiFinder
BIOTECH

Exhibition Partner

PeptiFinder Biotech is the pioneering CRO specializing in mRNA display technology. At PeptiFinder, we leverage a superior mRNA display platform featuring a variety of libraries (linear, monocyclic and bicyclic peptides) with ultra-high-diversity (up to 10¹⁵) which can be screened against nearly any biological target of interest rapidly (6-8 weeks) with a remarkable success rate of over 95%. By incorporating unnatural amino acids into cyclic peptide libraries, we can generate peptides with enhanced physiochemical properties and optimized pharmacokinetics. Additionally, we offer custom library designs tailored to specific client needs.

www.peptifinder.com

Get Involved



Molly Biggin

Partnerships Director

Tel: +1 617 455 4188

Email: sponsor@hansonwade.com



Syngene

Putting Science to Work

Exhibition Partner

Syngene International Ltd. is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's more than 6000 scientists offer both skills and the capacity to deliver great science, robust data security, and world-class manufacturing at speed to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, and Bristol-Myers Squibb as well as 2.2 Mn sq. ft of specialist facilities, Syngene works with biotech companies pursuing leading-edge science, such as GSK, Zoetis, and Merck KGaA.

www.syngeneintl.com



Media Partner

The Peptide Drug Hunting Consortium's mission is to support peptide drug hunting through shared knowledge, enabling the science-business interface, and sponsorship of entrepreneurial science and technology initiatives to empower breakthrough medicines.

www.peptidedrug hunting.org

“As we continue to unlock the potential of peptide therapeutics as a validated modality, it is invaluable to connect with the leading experts in the field to share our learnings and ensure our collective success in delivering these transformative therapies into the clinic and toward meaningful impact for patients”

Shelley Allen, Project Director II, Immuno- Pharmacology & Peptide Discovery, **Abbvie**

Get Involved



Molly Biggin

Partnerships Director

Tel: +1 617 455 4188

Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book



www.peptide-based-therapeutics-summit/register/



Tel: +1 617 455 4188



Email: info@hansonwade.com



Discover new case-study insights and takeaways to advance your peptide pipelines from leading peptide players including **Parabiosis Medicines**, **Merck & Co**, **Eli Lilly**, **Abbvie** and more



Collaborate with 100+ senior peptide executives across **pharma**, **biotech**, **investment**, **consultants** and **solution providers** to accelerate the innovation and progress towards clinical and commercial success



Share your research at the dedicated **scientific poster session**, engaging with peptide industry thought leaders and receive feedback towards the next breakthrough. Submit your abstract **here**.

Drug Developers*	Register by Friday, January 9 & Save up to \$1,000	On the Door Price
Conference + 2 Workshops	\$3,397 (Save \$1000)	\$4,397
Conference + 1 Workshop	\$2,998 (Save \$750)	\$3,748
Conference Only	\$2,599 (Save \$500)	\$3,099
Academic & Research Institutes**	Register by Friday, January 9 & Save up to \$1,000	On the Door Price
Conference + 2 Workshops	\$2,797 (Save \$1000)	\$3,797
Conference + 1 Workshop	\$2,498 (Save \$750)	\$3,248
Conference Only	\$2,199 (Save \$500)	\$2,699
Solution & Service Providers	Register by Friday, January 9 & Save up to \$1,000	On the Door Price
Conference + 2 Workshops	\$4,297 (Save \$1000)	\$5,297
Conference + 1 Workshop	\$3,798 (Save \$750)	\$4,548
Conference Only	\$3,299 (Save \$500)	\$3,799

*To qualify for the drug developer rate your company **must** have a **public drug pipeline** and **not offer fee-based services**. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for academic & research rate you must be a full-time academic. Please visit the website for full pricing options or email info@hansonwade.com
Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending.


Team Discounts***

- 10% discount – 2 Attendees
- 15% discount – 3 Attendees
- 20% discount – 4+ Attendees

***Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com



Venue

Hilton Boston Logan Airport
One Hotel Drive, Boston, MA 02128
www.hilton.com/en/hotels/boslhnh-hilton-boston-logan-airport

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom

